HETERO LABS LIMITED
Location
Telangana
Founded
1989-03-10
Website
Risk Signals
265 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about HETERO LABS LIMITED
Live alerts from global media, monitored by Business Radar
2025-02-11 (jdsupra.com)
ANDA Litigation Settlements - Winter 2024 | Robins Kaplan LLP - JDSupra
This chart summarizes the case name, drug, patents-in-suit, and publicly available terms for reported settlements in federal district court cases that...
Read more
2024-11-04 (medicaldialogues.in)
DoP rejects Glenmark's appeal on price cap of Clotrimazole Cream
New Delhi: The Department of Pharmaceuticals has upheld the National Pharmaceutical Pricing Authority's (NPPA) decision on the price cap for Clotrimazole Cream 1%, dismissing an appeal from Glenmark...
Read more
2024-09-10 (jdsupra.com)
Generically Speaking: A Hatch-Waxman Litigation Bulletin Second Quarter - Generic Launches
This chart tracks the date, drug, reference-listed company, applicant, and indications of publicly available drug launches resulting from Abbreviated...
Read more
2024-09-04 (medlegal360.com)
Valsartan Side Effects and the Legal Consequences
Across the nation, valsartan side effects lawsuits have been surfacing in connection with injuries brought on by this high blood pressure medication.
Read more
2024-06-18 (drugwatch.com)
Valsartan Lawsuit Settlement Nears for Hetero, But Fight Continues for Others
While valsartan lawsuits near settlement for some, Judge Bumb pushes for talks in losartan contamination cases. Less than 5% of cases are impacted by the current deal. Learn more about ongoing litigation.
Read more
2023-04-03 (indiatimes.com)
Supreme Court junks Hetero plea to quash quid pro quo case
The Supreme Court on Friday dismissed the pleas of pharmaceutical firm Hetero and its director M Srinivas Reddy to quash the CBI case filed against th
Read more
2022-01-06 (thewire.in)
The Zydus Cadila Remdesivir Fiasco Wasn’t an Isolated Incident – The Wire Science
Discussions with regulators and procurers suggest these agencies may have ignored many similar incidents during India's COVID-19 epidemic.
Read more
2013-02-25 (taz.de)
CDU pivot on gay marriage: signal for potential allies
The Christian Democrats are realigning themselves. The current Karlsruhe ruling on adoption law is more the reason than the cause.
Read more
(law360.com)
Janssen Gets Third Co. To Put Off Invokana Generic
Hetero Labs Ltd. has agreed to hold off on its generic version of Janssen's diabetes medication Invokana, putting an end to patent infringement litigation in New Jersey federal court.
Read more
(fiercepharma.com)
India's Hetero launches Avastin biosimilar, following Reliance into the market
Hyderabad-based Hetero Drugs has launched a biosimilar of Roche's ($RHHBY) colorectal cancer therapy Avastin (bevacizumab) in India, apparently overcoming a legal challenge by the Big Pharma linked | Hetero Drugs has launched a biosimilar of colorectal cancer therapy Avastin (bevacizumab) in India, apparently overcoming a legal challenge by Roche linked to language on the packaging label.
Read more
(indiatimes.com)
Sun Pharma, Hetero recall drugs in the US market, Health News, ET HealthWorld
Hetero: As per the USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. The Indian pharmaceutical industry is the world's third-largest by volume and 14th-largest in terms of value. India exported pharmaceuticals worth Rs 1,75,040 crore in the financial year 2021-22, including bulk drugs/ drug intermediates.
Read more
(law360.com)
Roxane Asks Fed. Circ. To Halt Hetero's Generic Kidney Drug
Roxane Laboratories Inc. blasted a New Jersey federal judge's ruling that a generic calcium acetate drug from Hetero Drugs Ltd. units likely doesn't infringe Roxane's kidney medication patent and should therefore be allowed on the market, explaining to a Federal Circuit panel Friday that the difference in capsule size between the two drugs is insignificant in view of the patent claims.
Read more